Yttrium-90 Labelled Anti-CD20 Radioimmunotherapy with Stem Cells Support

摘要: The use of 90Y-Ibritumomab-tiuxetan as a high dose regimen should be recommended for patients with high-risk relapsed/refractory lymphoma, who can tolerate high-dose chemotherapy treatment. Its restricted to clinical trials and particular care given dosimetric data; the whole therapy managed by multidisciplinary team. treatment administration exclusively performed in institutions which are licenced using, labelling administering radioactive material, Nuclear Medicine Divisions. In several countries licences specific type amount radionuclide: it is then requested proper licence Yttrium-90. Labelling easy procedures. However, equipments have available, including laminar flow shielded cell, shielding protection items, radionuclide activity calibrator, quality control devices well administration. patient has carried out protected environment. Full hospitalisation overnight stay appropriate trials. Pre-treatment dosimetry mandatory research protocols, radioimmunotherapy. It imaging 111Indium-labelled Ibritumomab-tiuxetan. Before administration, must informed about therapy, possible side effects, sign an consent. After on day discharge provide written behavioural instruction, also order prevent anxiety related issues.